STAT Summit Agenda

Wednesday, Nov. 20

5:00 p.m.

Registration

60 minutes

6:00 p.m.

Introduction

Matthew Herper, senior writer, medicine; editorial director, events, STAT

6:05 p.m.
SPONSOR SPEAKER

Welcome Remarks

Stephen J. Ubl, president and chief executive officer, PhRMA

6:10 p.m.

STAT Documentary Preview - "Augmented"

6:20 p.m.

The Future of Bionic Limbs

Matthew J. Carty, M.D., director, Lower Extremity Reconstruction Program, Brigham Health; staff surgeon, Division of Plastic Surgery, Brigham Health; associate professor, Harvard Medical School Jim Ewing, pioneering patient, The Ewing Amputation Hugh Herr, professor of media arts and sciences, Biomechatronics, MIT Media Lab Moderator: Alissa Ambrose, deputy director of multimedia and creative, STAT

In recent years, there have been amazing advances in artificial limbs. But what if patients could feel them, and start to think of them as their own? A look into a breakthrough project, taken from STAT’s documentary, “Augmented.”

6:45 p.m.

The Next Steps for Gilead Sciences

Daniel O’Day, M.B.A., chairman and chief executive officer, Gilead Sciences Interviewer: Adam Feuerstein, senior writer, biotech, STAT

Gilead helped make HIV a chronic disease and introduced a cure for hepatitis C. Several months in, its CEO talks about his plans for drugs that treat cancer and other diseases.

7:10 pm
SPONSOR SPEAKER

Closing Remarks

Philip Jones, Ph.D., vice president, Therapeutics Discovery, head of drug discovery, University of Texas MD Anderson Cancer Center

7:15 pm

Thank You

Rick Berke, co-founder and executive editor, STAT

7:20 pm

STAT Summit Welcome Reception

60 minutes

Brought to you by MD Anderson, the official sponsor of the 2019 STAT Wunderkinds

Thursday, Nov. 21

7:00 a.m.

Breakfast & Registration

60 minutes

8:00 a.m.

Introduction & Statement of Purpose

Linda Henry, managing director, STAT

8:05 a.m.
SPONSOR SPEAKER

Welcome Remarks

Stephen J. Ubl, president and chief executive officer, PhRMA

8:10 a.m.

Introducing the 2019 STAT Wunderkinds

Yamicia D. Connor, M.D., Ph.D., chief resident in Obstetrics and Gynecology at the Beth Israel Deaconess Medical Center; clinical fellow in Obstetrics, Gynecology, and Reproductive Biology at Harvard Medical School Sudhakar V. Nuti, M.D., M.Sc., Resident in primary care/internal medicine at Massachusetts General Hospital; researcher at the Yale Center for Outcomes Research and Evaluation Ritu Raman, Ph.D., Postdoctoral fellow, MIT Moderator: Rick Berke, co-founder and executive editor, STAT

These researchers will shape the future of medicine. Come meet them.

Sponsor Introduction
Jason Bock, Ph.D., vice president, therapeutics discovery, head of biologics product development, University of Texas MD Anderson Cancer Center
8:35 a.m.

Interview With A Gene Therapy Pioneer

James M. Wilson, M.D., Ph.D., director, Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania Interviewer: Sharon Begley, senior writer, science and discovery, STAT

For decades, gene therapy was a field in the wilderness, considered too risky to try and unlikely to be effective. Jim Wilson will tell us the story of moving from gene therapies.

8:55 a.m.
Sponsor Speaker

Moving from “Can We?” to “Should We?”

Anthony Yanni, M.D., M.B.D., senior vice president and global head of patient centricity, Astellas Interviewer: Rick Berke, co-founder and executive editor, STAT

The patient voice can add value throughout the process of developing and delivering innovative medicines. Here’s how to make sure that happens.

9:05 a.m.

Building on a Breakthrough

Jeffrey Leiden, M.D., Ph.D., chairman and chief executive officer, Vertex Pharmaceuticals Interviewer: Matthew Herper, senior writer, medicine; editorial director, events, STAT

This year, Vertex Pharmaceuticals introduced a new therapy that could dramatically improve the lives of 90% of patients with cystic fibrosis. Let’s talk about the benefits — and the costs.

9:30 a.m.
Sponsor Speaker

Where can AI take biomedicine?

Virginia Savova, principal senior scientist and lab head in precision immunology, immunology & inflammation therapeutic area, Sanofi

Virginia Savova started out deploying a new technology to understand why immune response fails in cancer. Now, at Sanofi, she aims to make AI a standard industry tool.

9:35 a.m.

More Money, Less Health.

Peter Bach, M.D., M.A.P.P., director of Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

In the US, financial incentives for innovation can be poorly aligned with the shared objectives of that innovation. Peter Bach explains why high drug prices today may be making us poorer and sicker.

9:45 a.m.

The State of Biotech

Athena Countouriotis, M.D., president and chief executive officer, Turning Point Therapeutics Jacqualyn Fouse, Ph.D., chief executive officer, Agios Pharmaceuticals Jeff Jonas, M.D., chief executive officer, Sage Therapeutics Nick Leschly, M.B.A. chief bluebird, bluebird bio Moderator: Adam Feuerstein, senior writer, biotech, STAT

We live in an age of miracles, but they come at a high cost — literally, with new gene therapies costing millions of dollars each. Can we afford them?

10:25 a.m.

Morning Break

30 minutes

Brought to you by National Pharmaceutical Council

10:55 a.m.

Can AI Fix Drug R&D?

Hal Barron, M.D., chief scientific officer and president, R&D, GlaxoSmithKline Daphne Koller, Ph.D., founder and chief executive officer, Insitro Aviv Regev, Ph.D., HHMI, MIT, and core institute member and chair of the faculty, Broad Institute of MIT and Harvard Moderator: Damian Garde, national biotech reporter, STAT

Artificial intelligence has been more hype than a reality in drug development. Some say that’s changing. Hear from some true believers.

11:30 a.m.
Sponsor Speaker

Ushering in a New Era for Health Care

Patrick Dey, vice president, digital health & innovation, Amgen Interviewer: Linda Henry, managing director, STAT

Major advancements in data availability and analytics techniques have paved the way for an overdue transformation in health care. What does the future of health care and patient support look like?

11:45 a.m.

Where No FDA Has Gone Before

Amy P. Abernethy, M.D., Ph.D., principal deputy commissioner and acting CIO, Food and Drug Administration Interviewer: Matthew Herper, senior writer, medicine; editorial director, events, STAT

A year ago, Amy Abernethy left industry to take a top job at the FDA. She’s come to talk about embracing technology, the promise (and limitations) of data from the real world, CBD, and more.

12:10 p.m.

Lunch

85 minutes

12:30 p.m.
Sponsor Speaker

Cell Therapy & the Potential to Revolutionize the Future of Cancer Treatment

Arie Belldegrun, M.D., FACS, executive chairman and co-founder, Allogene Therapeutics

1:30 p.m.

Call To Order & Introduction

Matthew Herper, senior writer, medicine; editorial director, events, STAT

1:35 p.m.

STAT Biomedical Innovation Award

Interviewer: Megan Thielking, Reporter, STAT

STAT, with the help of a panel of experts, will recognize a top researcher in biology or medicine whose work has helped to define their field, helping patients.

Sponsor Introduction
Morris Birnbaum, M.D., Ph.D., senior vice president, chief scientific officer, Pfizer
2:00 p.m.

The Hypebusters

Otis Brawley, M.D., Bloomberg Distinguished Professor of oncology and epidemiology, Johns Hopkins University Joel Dudley, Ph.D., senior vice president of research, Tempus Steve Nissen, M.D., MACC, chief academic officer for the Heart and Vascular Institute, Cleveland Clinic Moderator: Rebecca Robbins, San Francisco correspondent, STAT

With breakthroughs come hype. So we’ve assembled a crew who has had a role in spotting unsafe medicines, ineffective treatments, and outright fraud. They’ll tell us what to watch out for.

2:35 p.m.

Afternoon Break

30 minutes

Brought to you by National Pharmaceutical Council

3:05 p.m.

Nurturing Innovation in Academia

Sandra L. Fenwick, chief executive officer, Boston Children’s Hospital Laurie Glimcher, M.D., president and chief executive officer, Dana-Farber Cancer Institute Lloyd Minor, M.D., Carl and Elizabeth Naumann Dean, Stanford University School of Medicine Moderator: Gideon Gil, managing editor, STAT

It’s tough to pay for your innovation as an academic medical center. Three top administrators talk about what’s changing in medicine and where the next breakthroughs will come from.

Sponsor Introduction
Reenie McCarthy, chief executive officer, Stealth BioTherapeutics
3:30 p.m.
Sponsor Speaker

How Science and Culture Can Drive Tomorrow’s Inventions

Mark Namchuk, Ph.D., senior vice president, research, pharmaceutical, and non-clinical development, Alkermes Interviewer: Rick Berke, co-founder and executive editor, STAT

Inventing new drugs requires creating a culture that encourages both critical thinking about science and out-of-the-box risk-taking. Here, insights from years in the R&D trenches.

3:45 p.m.

Building the Next Big Thing

Julie Grant, M.B.A., partner, Canaan Sara Nayeem, M.D., M.B.A., partner, NEA Krishna Yeshwant, M.D., M.B.A., general partner, GV Moderator: Kate Sheridan, general assignment reporter, STAT

The business of venture capital consists of predicting the future and building new companies to embrace it. Three investors with experience in both will give us their thoughts on what’s next.

4:15 p.m.

What “Breakthrough” Means to Patients

David Fajgenbaum, M.D., M.B.A., M.Sc., co-founder and executive director, Castleman Disease Collaborative Network; author, "Chasing My Cure" Janet Freeman-Daily, M.S., lung cancer patient/activist, GrayConnections.net Matthew Might, Ph.D., director, Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham Moderator: Casey Ross, national technology correspondent, STAT

The people on this panel have faced deadly disease — either their own or a loved one’s. But in each case, they’ve decided to fight it in every way they can. Here is what they have learned.

Sponsor Introduction
Emmanuelle di Tomaso, Ph.D., vice president and head of oncology biomarkers, Bayer
4:55 p.m.

Building the New Bristol-Myers Squibb

Giovanni Caforio, M.D., chairman and chief executive officer, Bristol-Myers Squibb Interviewer: Matthew Herper, senior writer, medicine; editorial director, events, STAT

With its purchase of Celgene, the drug giant that created the cancer immunotherapy market is executing one of the biggest mergers in years. What will it mean for research?

5:20 p.m.

Can This Medicine Really Treat Alzheimer’s?

Alfred W. Sandrock, Jr., M.D., Ph.D., Executive vice president, research & development, and chief medical officer, Biogen Interviewer: Matthew Herper, senior writer, medicine; editorial director, events, STAT

Biogen has shocked the world twice this year: when it said aducanumab had not succeeded, and when it said that, actually, it had. The drug’s champion, Al Sandrock, joins us to explain one of the biggest turnabouts in drug development.

5:45 p.m.
Sponsor Speaker

Closing Remarks

Ramona Sequeira, M.B.A., president, United States business unit, Takeda

5:50 p.m.

Final Wrap-Up

Matthew Herper, senior writer, medicine; editorial director, events, STAT

5:55 p.m.

STAT Summit Closing Reception

60 minutes
Reception space brought to you by Vertex